Table 2:
Models | HR (95% CI) of HF per doubling of biomarker, P value | |||
---|---|---|---|---|
sCD14 | IL-6 | hsCRP | WBC | |
Model 1 | 1.95 (1.66–2.29) P<0.001 | 1.34 (1.27–1.41) P<0.00i | 1.20 (1.16–1.24) P<0.001 | 1.75 (1.57–1.95) P<0.001 |
Model 2 | 1.56 (1.29–1.89) P<0.001 | 1.18 (1.10–1.25), P<0.001 | 1.10 (1.06–1.15), P<0.001 | 1.24 (1.09–1.42), P<0.001 |
Model 3 | 1.34 (1.09–1.64) P<0.001 | 1.12 (1.04–1.20) P<0.001 | 1.05 (1.00–1.10) P=0.040 | 1.12 (0.96–1.29) P=0.142 |
CI = Confidence interval; HF = Heart failure; HR = Hazard ratio.
Model 1. Adjusted for age, sex, and race. (Participants in analysis: sCD14, n=5217; IL-6, n=4909; hsCRP, n=5192; WBC, n=5187.)
Model 2. Adjusted for covariates in Model 1 plus education, BMI, smoking, alcohol, physical activity score, systolic blood pressure, antihypertensive use, diabetes, estrogen use, LDL, HDL, eGFR, prevalent coronary heart disease, prevalent stroke, prevalent TIA, prevalent atrial fibrillation. (Participants in analysis: sCD14, n=4413; IL-6, n=4151; CRP, n=4399; WBC, n=4397.)
Model 3. Adjusted for covariates in Model 2 plus all other inflammatory biomarkers. (Participants in analysis: n=4142.)